Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MDLive vs Tablet Health

MDLive
Graded #358

Higher grade

vs+11.199999999999996
Tablet Health
Graded #495

Lower grade

The verdict

MDLive takes it — 58.8/100 to 47.6/100.

MDLive grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MDLive (an Evernorth/Cigna company) is a large telehealth provider offering urgent care, primary care, dermatology and behavioral health.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationMDLive +2
53
51
Clinical oversightMDLive +48
85
37
Labs & monitoringMDLive +4
54
50
FulfillmentMDLive +5
62
57
Contract termsEven
55
55
MDLive · left barTablet Health · right bar

The numbers

MetricMDLiveTablet Health
WeighScore58.8/10047.6/100
GradeCC
Scorecard rank#358#495
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
MDLive

Graded #358 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s including Wegovy and Zepbound
  • Covered through insurance and employer benefits for 50M-plus people
  • Board-certified physicians averaging about 15 years of experience
  • Part of Evernorth/Cigna, a large established healthcare organization
  • Offers full primary care, not just a single weight-loss funnel

Where it loses points

  • GLP-1s only at clinician discretion in a Primary Care routine visit
  • Anti-obesity meds not available in FL, LA, MS or NJ
  • Distributed mainly via insurers and employers; cost varies by plan
  • No transparent published monthly cash price for GLP-1 care
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard